Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
$0.02
$1K4.039,906 shsN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
$0.00
$0.00
$0.03
$6K0.779,936 shsN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
$0.00
$0.00
$0.00
$3K0.212,470 shsN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
$0.00
$0.00
$0.05
$4K1.94N/AN/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%-97.37%
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%+100.00%+100.00%0.00%-99.32%
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
0.00%0.00%0.00%0.00%0.00%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00
N/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
0.00
N/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$1.00M0.01N/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
-$2.11MN/A0.00N/AN/AN/AN/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
-$18MN/A0.00N/AN/AN/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/A

Insider Ownership

CompanyInsider Ownership
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
28.20%
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
8.90%
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
36.90%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
230.74 million28.00 millionNot Optionable
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
427.58 million17.40 millionNot Optionable
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
635.55 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Comera Life Sciences stock logo

Comera Life Sciences NASDAQ:CMRA

$0.0002 0.00 (0.00%)
As of 05/29/2025

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

FluoroPharma Medical stock logo

FluoroPharma Medical OTCMKTS:FPMI

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Sophiris Bio stock logo

Sophiris Bio OTCMKTS:SPHS

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.